Cytosorbents Crp
$ 0.66
8.20%
17 Apr - close price
- Market Cap 41,450,800 USD
- Current Price $ 0.66
- High / Low $ 0.67 / 0.60
- Stock P/E N/A
- Book Value 0.09
- EPS -0.13
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.96 %
- 52 Week High 1.39
- 52 Week Low 0.50
About
Cytosorbents Corporation, a critical care focused immunotherapy company, is dedicated to the research, development and commercialization of medical devices with its blood purification technology platform incorporating proprietary adsorbent and porous polymer technology. The company is headquartered in Monmouth Junction, New Jersey.
Analyst Target Price
$5.25
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-11 | 2025-11-13 | 2025-08-07 | 2025-05-07 | 2025-03-12 | 2024-11-07 | 2024-08-02 | 2024-05-09 | 2024-03-14 | 2023-11-10 | 2023-08-01 | 2023-05-02 |
| Reported EPS | -0.09 | -0.04 | 0.03 | -0.1441 | -0.14 | -0.04 | -0.08 | -0.12 | -0.13 | -0.21 | -0.14 | -0.17 |
| Estimated EPS | -0.0441 | -0.05 | -0.04 | -0.07 | -0.0533 | -0.06 | -0.1 | -0.12 | -0.14 | -0.14 | -0.11 | -0.13 |
| Surprise | -0.0459 | 0.01 | 0.07 | -0.0741 | -0.0867 | 0.02 | 0.02 | 0 | 0.01 | -0.07 | -0.03 | -0.04 |
| Surprise Percentage | -104.0816% | 20% | 175% | -105.8571% | -162.6642% | 33.3333% | 20% | 0% | 7.1429% | -50% | -27.2727% | -30.7692% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CTSO
2026-04-15 21:39:23
CytoSorbents Corporation filed an amended annual report (Form 10-K/A) to add detailed Part III information regarding governance, executive and director compensation, and security ownership. This amendment significantly includes disclosures on board composition, committee structures, director independence, and auditor fees, without altering previously reported financial statements. Key figures from the filing include a non-affiliate market value of $60.6 million as of June 30, 2025, and approximately 62.7 million shares outstanding as of March 20, 2026, alongside executive compensation details.
2026-03-30 11:10:53
Cytosorbents reported fiscal 2025 revenue of $37.1 million, a 4.1% increase year-over-year, and a narrowed net loss of $8.2 million. The company improved its gross profit to $26.5 million with a 71.5% margin and is focusing on cost reductions and operational realignment to achieve cash-flow break-even in the second half of 2026. Efforts include a strategic workforce reduction and preparing for a resubmission for FDA De Novo for DrugSorb-ATR.
2026-03-28 12:39:41
Cytosorbents Corp (CTSO) reported a 4% increase in full-year 2025 sales to $37.1 million, driven by international markets, despite a 10% decline in German sales and a net loss of $14.2 million. The company achieved strong gross margins and made progress with its DrugSorb-ATR program and PuriFi initiative, aiming for cash flow breakeven in the second half of 2026. However, operating expenses remained flat, and Q4 2025 revenue growth was modest at 1% year over year.
2026-03-27 12:09:21
Cytosorbents Corporation reported its Q4 and full-year 2025 earnings, with total sales up 4% to $37.1 million, driven by strong international performance, though German sales declined. The company is focused on a turnaround in Germany, advancing its DrugSorb-ATR program for U.S. market approval, and achieving cash flow breakeven in the second half of 2026 by optimizing its cost structure and improving operational efficiencies. Despite an initial FDA denial for DrugSorb-ATR, discussions are ongoing for a streamlined resubmission, supported by positive clinical trial data.
2026-03-26 20:41:53
CytoSorbents Corp. reported its financial results for Q4 and the full year 2025, showing a net loss of 9 cents per share for the fourth quarter and 13 cents per share for the entire year. The medical device company, based in Princeton, New Jersey, also reported revenue for both periods. The report also details market analysis for the water filter industry, focusing on demand, supply, trade, and price dynamics to support strategic planning.
2026-03-26 11:39:52
H.C. Wainwright reiterated a Neutral rating and a $0.75 price target for CytoSorbents (NASDAQ:CTSO) after the company reported its fourth-quarter and full-year 2025 financial results, which missed consensus estimates. Despite the stock trading below the target at $0.67, InvestingPro data suggests it may be undervalued. The firm expects modest sales growth of about 10% in 2026, driven by international partners, and believes the company's cash position is sufficient until Q3 2026.
